BMRN vs. ILMN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and ILMN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMRN | ILMN |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | Illumina, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 11.19 billion USD | 16.01 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | July 26, 1999 | July 28, 2000 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMRN and ILMN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | ILMN |
|---|---|---|
| 5-Day Price Return | -1.95% | 5.87% |
| 13-Week Price Return | -5.00% | 23.95% |
| 26-Week Price Return | -9.39% | -17.66% |
| 52-Week Price Return | -34.52% | -18.81% |
| Month-to-Date Return | 0.78% | -1.56% |
| Year-to-Date Return | -11.30% | -24.34% |
| 10-Day Avg. Volume | 3.38M | 2.25M |
| 3-Month Avg. Volume | 2.22M | 2.30M |
| 3-Month Volatility | 27.90% | 41.84% |
| Beta | 0.34 | 1.40 |
Profitability
Return on Equity (TTM)
BMRN
11.48%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, BMRN’s Return on Equity of 11.48% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
ILMN
55.15%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
ILMN’s Return on Equity of 55.15% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
BMRN
21.45%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 21.45% places BMRN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
ILMN
29.37%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
ILMN’s Net Profit Margin of 29.37% is exceptionally high, placing it well beyond the typical range for the Life Sciences Tools & Services industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
Operating Profit Margin (TTM)
BMRN
25.33%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 25.33% places BMRN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
ILMN
30.21%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 30.21% places ILMN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BMRN | ILMN |
|---|---|---|
| Return on Equity (TTM) | 11.48% | 55.15% |
| Return on Assets (TTM) | 9.24% | 20.47% |
| Net Profit Margin (TTM) | 21.45% | 29.37% |
| Operating Profit Margin (TTM) | 25.33% | 30.21% |
| Gross Profit Margin (TTM) | 79.56% | 66.55% |
Financial Strength
Current Ratio (MRQ)
BMRN
5.56
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BMRN’s Current Ratio of 5.56 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
ILMN
1.81
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
ILMN’s Current Ratio of 1.81 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
ILMN
0.88
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
ILMN’s leverage is in the upper quartile of the Life Sciences Tools & Services industry, with a Debt-to-Equity Ratio of 0.88. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
ILMN
-2.28
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
ILMN has a negative Interest Coverage Ratio of -2.28. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | BMRN | ILMN |
|---|---|---|
| Current Ratio (MRQ) | 5.56 | 1.81 |
| Quick Ratio (MRQ) | 3.60 | 1.28 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 0.88 |
| Interest Coverage Ratio (TTM) | -21.18 | -2.28 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
ILMN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
ILMN
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
ILMN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BMRN | ILMN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
16.81
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
BMRN’s P/E Ratio of 16.81 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
ILMN
12.32
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
In the lower quartile for the Life Sciences Tools & Services industry, ILMN’s P/E Ratio of 12.32 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
BMRN
3.61
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.61 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
ILMN
3.62
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
ILMN’s P/S Ratio of 3.62 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
BMRN
1.75
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BMRN’s P/B Ratio of 1.75 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
ILMN
6.69
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
ILMN’s P/B Ratio of 6.69 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | BMRN | ILMN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.81 | 12.32 |
| Price-to-Sales Ratio (TTM) | 3.61 | 3.62 |
| Price-to-Book Ratio (MRQ) | 1.75 | 6.69 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.99 | 15.04 |